Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ACADIA Pharmaceuticals Inc.    ACAD

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

ACADIA Pharmaceuticals Inc. : & SUPERVALU Inc. Announcements: (NASDAQ: ACAD), (NYSE: SVU)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/22/2013 | 08:25am CET

New York (March 22nd, 2013) - ACADIA Pharmaceuticals Inc.(NASDAQ: ACAD) announced that Jeffrey Cummings, M.D., Sc.D., Director of Cleveland Clinic Lou Ruvo Center for Brain Health, presented detailed results from ACADIA’s pivotal Phase III -020 Study with pimavanserin in patients with Parkinson’s disease psychosis at the Emerging Science session of the 65th American Academy of Neurology (AAN) Annual Meeting.

The analysis of the full data set from the Phase III -020 Study showed robust and consistent efficacy of pimavanserin across a wide array of study measures and confirmed the positive top-line results previously reported.

“The significant and consistent results observed across measures in the Phase III -020 Study are impressive and potentially very encouraging for Parkinson’s patients who suffer from the psychosis frequently associated with this disease,” said Dr. Jeffrey Cummings.

Find out if this announcement could benefit ACAD in the very short term here:

http://www.wallstreetscoop.net/market-scan/?symbol=ACAD


SUPERVALU Inc. (NYSE: SVU) announced it completed the sale of its Albertsons, Acme, Jewel-Osco, Shaw’s and Star Market stores and related Osco and Sav-on in-store pharmacies to AB Acquisition LLC, an affiliate of a Cerberus Capital Management L.P.-led investor consortium, in a stock deal valued at $3.3 billion, including $100 million in cash and $3.2 billion in debt assumption.

Operations for these banners will transfer overnight, and the new SUPERVALU will open for business on Friday as a more efficient wholesale and retail company with annual sales of approximately $17 billion.

As part of the transaction, SUPERVALU also announced that Symphony Investors, a Cerberus-led investor consortium, completed its tender offer resulting in the acquisition of 11,686,406 shares (approximately 5.475 percent of SUPERVALU’s outstanding common stock) at a purchase price of $4.00 per share in cash.

Find out more on SVU here:

http://www.wallstreetscoop.net/market-scan/?symbol=SVU


About Us:

WallStreetScoop.net issues momentum alerts on stocks that can provide gains to day traders and short-term investors. WallStreetScoop.net provides members with timely information and exclusive alerts on under-valued stocks in the United States with the potential to deliver short-term gains.

WallStreetScoop.net monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals WallStreetScoop.net is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading small cap stocks. Gain an Edge by joining the WallStreetScoop.net newsletter and receiving alerts from a Pro-Active team of researchers. Wall Street Scoop believes traders should have a chance at successfully trading Small stocks and invites traders and investors to be part of the free membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.WallStreetScoop.net

Disclosure: WallStreetScoop.net is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetScoop.Net website, for complete risks and disclosures.

Investor Alley, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.

For full disclaimer visit: www.wallstreetscoop.net/disclaimer/

Contact Info:
Thomas Greene
Wall Street Scoop
info@wallstreetscoop.net
347-905-5009


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ACADIA PHARMACEUTICALS INC
12/01 ACADIA PHARMACEUTICALS : Initiates Phase II Trial of Pimavanserin for Adjunctive..
11/15 ACADIA PHARMACEUTICALS : Initiates Phase II Trial of Pimavanserin for Adjunctive..
11/10 ACADIA PHARMACEUTICALS : to Announce Third Quarter 2016 Financial Results on Nov..
11/10 GLOBAL GLAUCOMA THERAPEUTICS DEVICES : Allergan Inc, Merck and Co. Inc, Novartis..
11/09 ACADIA PHARMACEUTICALS : jumps on drug sales
11/08 ACADIA PHARMACEUTICALS INC. : (ACAD) is Trading Higher on Unusual Volume for Nov..
11/07 ACADIA PHARMACEUTICALS : reports 3Q loss
11/07 ACADIA PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDI..
11/07 ACADIA PHARMACEUTICALS INC : Results of Operations and Financial Condition, Fina..
11/07 ACADIA PHARMACEUTICALS : Reports Third Quarter 2016 Financial Results
More news
Sector news : Biotechnology & Medical Research - NEC
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
12/02 Acadia After Nuplazid Approval
12/01 ACADIA launches mid-stage study of NUPLAZID in MDD
11/22 ACADIA PHARMACEUTICALS : Q3 Numbers Bode Well For 2017 Growth Outlook
11/18 Cerecor's Trial Of CERC-301 In Depression Offers Investors Potential Upside
11/15 ACADIA launches mid-stage study of NUPLAZID as adjunctive therapy in patients..
Advertisement
Financials ($)
Sales 2016 14,4 M
EBIT 2016 -273 M
Net income 2016 -276 M
Finance 2016 18,1 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 227x
EV / Sales 2017 40,1x
Capitalization 3 288 M
More Financials
Chart ACADIA PHARMACEUTICALS INC
Duration : Period :
ACADIA Pharmaceuticals Inc Technical Analysis Chart | ACAD | US0042251084 | 4-Traders
Full-screen chart
Technical analysis trends ACADIA PHARMACEUT...
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 40,6 $
Spread / Average Target 50%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stephen R. Davis President, Chief Executive Officer & Director
Stephen R. Biggar Chairman
James A. Nash Vice President-Technology Development & Operations
Todd S. Young EVP, Chief Financial & Accounting Officer
James Owen Chief Medical Officer & SVP-Clinical Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ACADIA PHARMACEUTICALS..-24.29%3 288
INCYTE CORPORATION-5.68%19 219
QUINTILES IMS HOLDINGS..11.90%18 225
CELLTRION, INC.--.--%9 953
SEATTLE GENETICS, INC.44.41%9 442
LONZA GROUP AG11.34%9 247
More Results